Prostate Cancer Stem Cell-Targeted Efficacy of a New-Generation Taxoid, SBT-1214 and Novel Polyenolic Zinc-Binding Curcuminoid, CMC2.24

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Botchkina, Galina I ^a,b   Zuniga, Edison S ^b   Rowehl, Rebecca H ^a   Park, Rosa ^a   Bhalla, Rahuldev ^a   Bialkowska, Agnieszka B ^a   Johnson, Francis ^b   Golub, Lorne M ^b   Zhang, Yu ^b   Ojima, Iwao ^b   Shroyer, Kenneth R ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CMC 224; COLLAGEN TYPE 1; CURCUMIN; HERMES ANTIGEN; PACLITAXEL; PROTEIN P21; PROTEIN P53; SBT 1214; TAXOID; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PROSTATE CANCER; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR SPHEROID;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CURCUMIN; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884556308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069884     Document Type: Article

References (71)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, (2011) Global Cancer Statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. van Brussel JP, Mickisch GH, (2003) Multidrug resistance in prostate cancer. Onkologie 26: 175-181. doi:10.1159/000071510. PubMed: 12771527.
3. Zivi A, Massard C, De-Bono J, (2010) Changing therapeutic paradigms in castrate-resistant prostate cancer. Clin Genitourin Cancer 8: 17-22. doi:10.3816/CGC.2010.n.003. PubMed: 21208851.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111. doi:10.1038/35102167. PubMed: 11689955.
5. Nautiyal J, Du J, Yu Y, Kanwar SS, Levi E, Majumdar AP, (2012) EGFR regulation of colon cancer stem-like cells during aging and in response to the colonic carcinogen dimethylhydrazine. Am J Physiol Gastrointest Liver Physiol 302(7):: G655-G663. doi:10.1152/ajpgi.00323.2011. PubMed: 22281474.
6. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, et al. (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66: 7843-7848. doi:10.1158/0008-5472.CAN-06-1010. PubMed: 16912155.
7. Dirks PB, (2006) Cancer: Stem cells and brain tumours. Nature 444: 687-688. doi:10.1038/444687a. PubMed: 17151644.
8. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, et al. (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402. doi:10.1016/j.stem.2007.08.001. PubMed: 18371377.
9. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM, (2007) WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 104: 618-623. doi:10.1073/pnas.0606599104. PubMed: 17202265.
10. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, et al. (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLOS ONE 3: e2428. doi:10.1371/journal.pone.0002428. PubMed: 18560594.
11. Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, et al. (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106: 162881-116286. PubMed: 19805294.
12. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, et al. (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235. doi:10.1016/j.stem.2009.01.007. PubMed: 19265662.
13. Mimeault M, Batra SK, SK (2010) New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol Histopathol 25: 1057-1073. PubMed: 20552555.
14. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman, MM14 Gillet JP, Calcagno AM, Varma S, Marino M, Green LJet al (2011) Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A 108: 18708-18713. doi:10.1073/pnas.1111840108. PubMed: 22068913.
15. Hutchinson L, Kirk Rebecca (2011) High drug attrition rates - where are we going wrong? Nat Rev Clin Oncol 8: 189-190. doi:10.1038/nrclinonc.2011.34. PubMed: 21448176.
16. Peehl DM, (2004) Are primary cultures realistic models of prostate cancer? J Cell Biochem 91: 185-195. doi:10.1002/jcb.10691. PubMed: 14689590.
17. Patrawala L, Calhoun T, Schneider-Broussardected ou J, Claypool K, Tang DG (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219.
18. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell 1: 313-323. doi:10.1016/j.stem.2007.06.002. PubMed: 18371365.
19. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim, JS19 Miki J, Furusato B, Li H, Gu Y, Takahashi Het al (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67(7):: 3153-3161. doi:10.1158/0008-5472.CAN-06-4429. PubMed: 17409422.
20. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, et al. (2009) Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26(5):: 433-446. doi:10.1007/s10585-009-9242-2. PubMed: 19221883.
21. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON, (2010) Identification of a cell of origin for human prostate cancer. Science 329: 568-571. doi:10.1126/science.1189992. PubMed: 20671189.
22. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, et al. (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500. doi:10.1038/nature08361. PubMed: 19741607.
23. Guo C, Liu H, Zhang BH, Cadaneanu RM, Mayle AM, et al. (2012) Epcam, CD44, and CD49f Distinguish Sphere-Forming Human Prostate Basal Cells from a Subpopulation with Predominant Tubule Initiation Capability. PLOS ONE 7(4):: e34219. doi:10.1371/journal.pone.0034219. PubMed: 22514625.
24. Kuznetsova L, Chen J, Sun L, Wu X, Pepe A, et al. (2006) Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett 16: 974-977. doi:10.1016/j.bmcl.2005.10.089. PubMed: 16298526.
25. Botchkina GI, Zuniga ES, Das M, Wang Y, Wang H, et al. (2010) New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheriods induced by purified colon tumor-initiating cells. Mol Cancer 9: 192-204. doi:10.1186/1476-4598-9-192. PubMed: 20630067.
26. Mimeault M, Batra SK, (2011) Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med 6: 31. doi:10.1186/1749-8546-6-31. PubMed: 21859497.
27. Shankar S, Srivastava RK, (2007) Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 30: 905-918. PubMed: 17332930.
28. Piantino CB, Salvadori FA, Ayres PP, Kato RB, Srougi V, et al. (2009) An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines. Int Braz J Urol 35: 354-360. doi:10.1590/S1677-55382009000300012. PubMed: 19538771.
29. Zhang Y, Gu Y, Lee H-M, Hambardjieva K, Vranková L, et al. (2012) Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem 19(25):: 4348-4358. doi:10.2174/092986712802884295. PubMed: 22830350.
30. Rowehl RH, Crawford H, Dufour A, Leyfman Y, Ju J, Botchkina GI, (2008) Genomic Analysis of Prostate Cancer Stem Cells Isolated from Highly Metastatic Cell Line. Cancer Genomics Proteomics 5: 301-309. PubMed: 19287071.
31. Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MSJ, Crawford H, et al. (2009) Phenotypic Subpopulations of Metastatic Colon Cancer Stem Cells. Cancer Genomics Proteomics 6: 19-30. PubMed: 19451087.
32. Botchkina GI, Ojima I, (2011) Prostate and colon cancer stem cells as a target for anti- cancer drug development. In Cancer Stem Cells Theories and Practice. Shostak S, eds. Intech: pp. 135-154.
33. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, et al. (2008) Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 9: R83. doi:10.1186/gb-2008-9-5-r83. PubMed: 18492237.
34. Kelly K, Yin JJ, (2008) Prostate cancer and metastasis initiating stem cells. Cell Res 18: 528-537. doi:10.1038/cr.2008.50. PubMed: 18414448.
35. Bisson I, Prowse DM, (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19: 683-697. doi:10.1038/cr.2009.43. PubMed: 19365403.
36. Verras M, Sun Z, (2006) Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 237: 22-32. doi:10.1016/j.canlet.2005.06.004. PubMed: 16023783.
37. Hall CL, Zhang H, Baile S, Ljungman M, Kuhstoss S, Keller ET, (2010) p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Res 70: 9916-9926. doi:10.1158/0008-5472.CAN-10-0440. PubMed: 21098705.
38. Bae K-M, Parker NN, Dai Y, Vieweg J, Siemann DW, (2011) E-cadherin plasticity in prostate cancer stem cell invasion. Am J Cancer Res 1: 71-84. PubMed: 21968440.
39. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang A-Y, et al. (2007) Roles for the Stem Cell-Associated Intermediate Filament Nestin in Prostate Cancer Migration and Metastasis. Cancer Res 67: 9199-9206. doi:10.1158/0008-5472.CAN-07-0806. PubMed: 17909025.
40. Zhao Y, Yan Q, Long X, Chen X, Wang Y, (2008) Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 26: 571-577. doi:10.1002/cbf.1478. PubMed: 18464297.
41. Attard G, Rizzo S, Ledaki I, Clark J, Reid AH, et al. (2009) A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies. Prostate 69(14):: 1507-1520. doi:10.1002/pros.20997. PubMed: 19544327.
42. Uzgare AR, Xu Y, Isaacs JT, (2004) In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 91: 196-205. doi:10.1002/jcb.10764. PubMed: 14689591.
43. Peehl DM, (2005) Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 12: 19-47. doi:10.1677/erc.1.00795. PubMed: 15788637.
44. Signoretti S, Waltregny D, Dilks J, et al. (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157: 1769-1775. doi:10.1016/S0002-9440(10)64814-6. PubMed: 11106548.
45. Di Como CJ, Urist MJ, Babayan I, et al. (2002) p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8: 494-501. PubMed: 11839669.
46. Oliai BR, Kahane H, Epstein JI, (2002) Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34βE12) antibody. Am J Surg Pathol 26: 1151-1160. doi:10.1097/00000478-200209000-00005. PubMed: 12218571.
47. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA, (2002) Comparison of the basal cell-specific markers, 34βE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 26: 1161-1168. doi:10.1097/00000478-200209000-00006. PubMed: 12218572.
48. Aaltomaa S, Lipponen P, Ala-Opas M, Kosma V-M, (2001) Downregulation of CD44 Expression and Prognostic Value of CD44 Standard and Variant v3 and v6 Isoforms in Prostate Cancer. Eur Urol 39: 138-144. doi:10.1159/000052428. PubMed: 11223672.
49. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H, (1998) Expression of CD44 Variant Exon 6 in Stage I Non-Small Cell Lung Carcinoma as a Prognostic Factor. Cancer Res 58: 1108-1110. PubMed: 9515789.
50. Alam TN, O'Hare MJ, Laczkó I, Freeman A, Al-Beidh F, et al. (2004) Differential expression of CD44 during human prostate epithelial cell differentiation. J Histochem Cytochem 52: 1083-1090. doi:10.1369/jhc.4A6256.2004. PubMed: 15258184.
51. Weihua Z, Lin Q, Ramoth AJ, Fan D, Fidler IJ, (2011) Formation of solid tumors by a single multinucleated cancer cell. Cancer 117: 4092-4099. doi:10.1002/cncr.26021. PubMed: 21365635.
52. Matsuda Y, Naito Z, Kawahara K, Nakazawa N, Korc M, Ishiwata T, (2011) Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biol Ther 11: 512-523. doi:10.4161/cbt.11.5.14673. PubMed: 21258211.
53. Fusi A, Reichelt U, Busse A, Ochsenreither S, Rietz A, et al. (2011) Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. J Invest Dermatol 131: 487-494. doi:10.1038/jid.2010.285. PubMed: 20882037.
54. Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, et al. (2012) Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 11(2):: 329-339. doi:10.1158/1535-7163.MCT-11-0289. PubMed: 22027694.
55. Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, Mahato RI, (2012) Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway. PLOS ONE 7: e40021. doi:10.1371/journal.pone.0040021. PubMed: 22768203.
56. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP, (2009) Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Transl Oncol 2: 321-328. PubMed: 19956394.
57. Fong D, Yeh A, Naftalovich R, Choi TH, Chan MM, (2010) Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett 293: 65-72. doi:10.1016/j.canlet.2009.12.018. PubMed: 20089354.
58. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, et al. (2010) Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 122: 777-785. doi:10.1007/s10549-009-0612-x. PubMed: 19898931.
59. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, et al. (2011) Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLOS ONE 6: e17850. doi:10.1371/journal.pone.0017850. PubMed: 21408027.
60. Aggarwal BB, Sundaram C, Malani N, Ichikawa H, (2007) Curcumin: the Indian solid gold. Adv Exp Med Biol 595: 1-75. doi:10.1007/978-0-387-46401-5_1. PubMed: 17569205.
61. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Pu YS, (2002) Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. Prostate 51: 211-218. doi:10.1002/pros.10089. PubMed: 11967955.
62. Su CC, Lin JG, Li TM, Chung JG, Yang JS, et al. (2006) Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3. Anticancer Res 26: 4379-4389. PubMed: 17201158.
63. Matsushima H, Sasaki T, Goto T, Hosaka Y, Homma Y, et al. (1998) Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol 29: 778-783. doi:10.1016/S0046-8177(98)90445-2. PubMed: 9712417.
64. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, et al. (2000) The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 6: 1896-1899. PubMed: 10815913.
65. Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P, Dahiya R, (2000) Deletion of Y-chromosome specific genes in human prostate cancer. J Urol 163: 1339-1342. doi:10.1016/S0022-5347(05)67774-9. PubMed: 10737540.
66. Vijayakumar S, Garcia D, Hensel CH, Banerjee M, Bracht T, et al. (2005) The human Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice. Genes Chromosomes Cancer 44: 365-372. doi:10.1002/gcc.20250. PubMed: 16080199.
67. Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Löhrs U, (1994) Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res 54: 4472-4480. PubMed: 8044798.
68. Miyoshi Y, Uemura H, Fujinami K, Mikata K, Harada M, et al. (2000) Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 43: 225-232. doi:10.1002/(SICI)1097-0045(20000515)43:3. PubMed: 10797498.
69. Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, et al. (1995) Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 147: 1608-1614. PubMed: 7495286.
70. Luo JH, Yu YP, (2003) Genetic factors underlying prostate cancer. Expert Rev Mol Med 5: 1-26. PubMed: 14585168.
71. Nieländer I, Martín-Subero JI, Wagner F, Baudis M, Gesk S, et al. (2008) Recurrent loss of the Y chromosome and homozygous deletions within the pseudo-autosomal region 1: association with male predominance in mantle cell lymphoma. Haematol 93: 949-950. doi:10.3324/haematol.12656.